- Open Access
Resection of the vaginal vault for vaginal recurrence of cervical cancer after hysterectomy and brachytherapy
© Abe et al.; licensee BioMed Central. 2015
- Received: 17 September 2014
- Accepted: 1 February 2015
- Published: 2 April 2015
We describe our experiences with vaginal vault resection for vaginal recurrence of cervical cancer after hysterectomy and radiotherapy. After operative treatment, the rate of vaginal vault recurrence of uterine cervical cancer is reported to be about 5%. There is no consensus regarding the treatment for these cases.
Between 2004 and 2012, eight patients with vaginal vault recurrence underwent removal of the vaginal wall via laparotomy after hysterectomy and radiotherapy.
The median patient age was 45 years (range 35 to 70 years). The median operation time was 244.5 min (range 172 to 590 min), the median estimated blood loss was 362.5 mL (range 49 to 1,890 mL), and the median duration of hospitalization was 24.5 days (range 11 to 50 days). Two patients had intraoperative complications: a grade 1 bowel injury and a grade 1 bladder injury. The following postoperative complications were observed: one patient had vaginal vault bleeding, three patients developed vesicovaginal fistulae, and one patient had repeated ileus. Two patients needed clean intermittent catheterization. Local control was achieved in five of the eight cases.
Vaginal vault resection is an effective treatment for vaginal recurrence of cervical cancer after hysterectomy and radiotherapy. However, complications of this procedure can be expected to reduce quality of life. Therefore, this operation should be selected with great care.
- Cervical cancer
- Vaginal recurrence
- Vaginal vault resection
- Postoperative complications
Cervical cancer is the fourth most common cancer in women worldwide. In 2012, 528,000 cases of cervical cancer were diagnosed globally and 266,000 deaths were attributed to this disease . In Japan, the incidence of early stage cervical cancer is increasing among younger women . There are many long-term survivors of these cancers, and those who experience locoregional recurrence after initial surgery may require radiotherapy . In most cases, radiotherapy can control vaginal vault recurrence [4,5], but additional relapse is occasionally experienced. If it is feasible, surgical resection is generally considered for such cases. Vaginal vault resection is a technique that is applicable to rare clinical cases. Only a few reports have described the efficacy of laparoscopic or vaginal vaginectomy [6,7]. To the best of our knowledge, this is the first study to report on vault resection performed via laparotomy. In the present study, we aimed to describe the efficacy and feasibility of vaginal vault resection by laparotomy for isolated small vaginal relapse of cervical cancer.
Clinical features of the patients at the initial operation
AS in situ
MRH + BSO + PLA
RH + BSO + PLA
MRH + BSO
RH + BSO + PLA
Adaptation of radiation treatment
Interval between initial operation and vaginectomy
Some patients had been treated with radiation using remote afterloading systems for positive margins of hysterectomy, and other patients had been treated for first vaginal vault recurrence after hysterectomy. After brachytherapy, some patients developed vaginal vault recurrence. Recurrences were treated with vaginal vault resection by laparotomy in eight cases. The intervals between brachytherapy and vaginal vault recurrences varied from 9 to 44 months. The patients were asked to indicate that they understood the nature of the surgical procedure, operative complications, and postoperative complications.
Patient characteristics at the initial operation are summarized in Table 1. The median patient age was 45 years (range 35 to 70 years), the median body mass index was 19.7 (range 16.8 to 24.5), and all patients met the criteria for American Society of Anesthesiologists physical status (PS) classification 1 to 2. Three patients were diagnosed with carcinoma in situ: one patient was diagnosed with carcinoma in situ, one patient was diagnosed with adenosquamous cell carcinoma in situ, and one patient was diagnosed with adenocarcinoma in situ. Three patients had stage Ia disease: two had squamous cell carcinoma, and one had adenocarcinoma. Two patients had stage II disease: one had squamous cell carcinoma and one had adenosquamous cell carcinoma. Vaginal surgical margins were positive in three cases, negative in three cases, and unavailable in two cases.
Clinical feature of the patients at vaginectomy
Operative time (min), for vaginectomy
Blood loss, mL
Rectal injury G1
Bladder injury G1
Vesicovaginal fistula (POD33)
Vesicovaginal fistula (POD40), ileus, nephritis
Vesicovaginal fistula (POD19), nephritis
Margin of resection
Site of recurrence after colpectomy
Treatment for recurrence after colpectomy
Vulvectomy + lymphadenectomy
Time to recurrence from colpectomy
Two patients showed lymph node involvement after treatment for relapse. One of these patients had pelvic lymph node metastasis and was treated with radiotherapy. The other had para-aortic lymph node metastasis and was treated with chemotherapy. At the last follow-up, both patients were alive and well, with no evidence of disease. A patient with locoregional failure showed recurrence in the vagina, and pelvic exenteration and ureteroileostomy were performed. This patient died due to peritoneal dissemination 23 months after vaginal resection. A patient with locoregional and distant failure showed recurrence in the vulva after vaginal vault resection. The tumor was partially resected from the vulva. Furthermore, this patient developed multiple liver metastases 30 months later. With respect to postoperative complications, repeated ileus was managed with some difficulty. After a symptom was improved by fasting, this patient was treated with TS-1, resulting in the shrinkage of the recurrent tumors, and proton beam therapy was performed. Forty-five months after vaginal vault resection, the patient was alive with disease at the last follow-up.
The rate of vaginal vault recurrence of stages I to II uterine cervical cancer after operative treatment has been reported to be 4.9% . No consensus has been reached regarding the selection of multimodal treatment strategies. In general, radiotherapy is effective in terms of local control with vaginal vault recurrence. We treated first vaginal relapse with radiotherapy, and although 95% patients were cured at our hospital, we sometimes observed second vaginal failures after providing radiotherapy for first vaginal relapse.
In a prior study, Berek et al. noted that intent-to-cure recurrent cervical carcinoma was the indication for pelvic exenteration after prior pelvic radiotherapy . Although they found pelvic exenteration to be a feasible surgical procedure, it was associated with severe complications. Accordingly, Berek et al. described using pelvic exenteration as a last option for surgical therapy.
Panici et al. reported that the complications of pelvic exenteration include the development of ileus in 42% of patients (5/12), the requirement of re-laparotomy in 17% of patients (2/12), and the occurrence of leaks after intestinal anastomosis in 37.5% of patients (3/8) . Panici et al.’s report further showed that the median operative time was 491.5 min, the estimated blood loss was 2537.5 mL, and the median hospital stay was 65.5 days. Another report has also shown similar results, including major and minor complication rates of 34% and 57%, respectively . Complete resection with exenteration is a significant prognostic factor for local control and survival, but it is also associated with high morbidity.
We have treated first vaginal relapse with radiotherapy and performed surgery for second vaginal failures. In consideration of morbidity, we have used surgery for resection of the vaginal vault, instead of using pelvic exenteration. The indication of resection for vault failure after hysterectomy and radiation included the following: 1) superficially carcinoma, 2) an interval of greater than 6 months between the initial operation and vault failure, and 3) consensus for the presence of both operative and postoperative complications. In this study, we have reported eight patients with vault failures who underwent vault resection.
Choi et al. reported four cases of laparoscopic upper vaginectomy for vaginal intraepithelial neoplasia and superficially invasive vaginal carcinoma after hysterectomy without radiotherapy . Their operations were adapted for a recurrent lesion in the upper third of the vagina, and laparoscopic upper vaginectomy succeeded in controlling these cases without second vault failure.
Panici et al. reported cases in which vaginectomies were performed in patients who underwent radical hysterectomy without pelvic radiotherapy . In this series, early postoperative complications were experienced by seven of the patients who had undergone vaginal vaginectomy: four patients developed vaginal scar abscess dehiscence, two experienced postoperative bleeding, and one developed a vesicovaginal fistula. Six subsequent complications were also observed: three patients developed vaginal stenosis, two patients developed urinary incontinence, and one patient developed ureteral stenosis. After vaginectomy, seven patients developed metastases, but no patient developed a second vaginal failure. Five-year overall and progression-free survival rates were 70.5% and 59.4%, respectively. Panici et al. concluded that vaginal vaginectomy was feasible in selected patients. Their study’s selection criteria were as follows: patients were included if they had vaginal lesions <2 cm in size that were not juxtaposed to the rectum or bladder, and patients were excluded if they had prior radiation, prior nodal metastasis, palpable paravaginal invasion, or positive results in examinations for metastasis (including positron emission tomography (PET)). The criteria for performing a pre-operative PET-computed tomography were the absence of both bulky tumor and distant disease.
In contrast to these previous reports, radiotherapy had been already performed in our study because of its good efficacy. At the second vault failure after radiotherapy, resection of the vault was performed via laparotomy. Total vaginectomy resulted in complications (grade 3, 37.5%; 3/8) because of the adherence of the bladder and rectum after the first surgery and radiotherapy. Bladder filling was used to identify the altered anatomy after prior hysterectomy, as well as the induration of the vaginal vault leading to the bladder, vaginal apex, and border. Postoperative repeated cystitis and neurogenic bladder required longer hospitalization. Three patients developed vesicovaginal fistulae, which are associated with a high risk of severe complications. Vesicovaginal fistulae were managed conservatively, and fortunately, each of the patient’s fistulae closed spontaneously. Technically feasible procedures could result in maintained bladder or bowel function.
Although this report is somewhat limited by the small number of patients, our results suggest that vaginectomy after radiotherapy is effective. In this series, local control was achieved in five cases. Since vaginal resection can be performed to achieve local control, this surgery is an option for vaginal vault recurrence, as is pelvic exenteration. However, an earlier study showed higher complication rates when this operation was performed after hysterectomy and brachytherapy. Because of the associated complications, vaginectomy should only be selected after carefully considering possible alternatives. For patients who have been selected carefully, vaginal resection is an acceptable treatment option.
Because of the rarity of the cases that we have considered, single-institution studies with large sample are likely to be infeasible. We suggest that data pooling is the most promising avenue for identifying optimal therapies and achieving other progress in this field. Such data pooling could come in the form of a review of all previously published case reports, case series, and small studies; the organization of prospective, multicenter case series; and/or the referral of all similar cases in Japan to a select group of medical institutes.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
We sincerely thank Dr. Takazawa Y (Cancer Institute Hospital).
- International Agency for Research on Cancer. Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. World Health Organization; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=cervix
- Yamagami W, Aoki D. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2014;40:338–48.View ArticleGoogle Scholar
- Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer. 1993;3:193–8.View ArticlePubMedGoogle Scholar
- Jobsen JJ, Leer JW, Cleton FJ, Hermans J. Treatment of locoregional recurrence of carcinoma of the cervix by radiotherapy after primary surgery. Gynecol Oncol. 1989;33:368–71.View ArticlePubMedGoogle Scholar
- Ito H, Shigematsu N, Kawada T, Kubo A, Isobe K, Hara R. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol. 1997;67:154–61.View ArticlePubMedGoogle Scholar
- Choi YJ, Hur SY, Park JS, Lee KH. Laparoscopic upper vaginectomy for post-hysterectomy high risk vaginal intraepithelial neoplasia and superficially invasive vaginal carcinoma. J Surg Oncol. 2013;11:126–30.Google Scholar
- Panici PB, Manci N, Bellati F, Di Donato V, Marchetti C, De Falco C, et al. Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence. Int J Gynecol Cancer. 2009;19:1625–31.View ArticleGoogle Scholar
- Nakayama K, Teshima H, Hirai Y, Hasumi K, Masubuchi K. Stump recurrence after radical hysterectomy for patients with uterine cervical cancer (in Japanese). Nihon Sanka Fujinka Gakkai Zasshi. 1990;42:241–5.PubMedGoogle Scholar
- Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005;99:153–9.View ArticlePubMedGoogle Scholar
- Ferenschild FTJ, Vermaas M, Vehoef C, Ansink AC, Kirkels WJ, Eggermont AMM, et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg. 2009;33:1502–8.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.